Last reviewed · How we verify
Ritonavir-boosted lopinavir — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Ritonavir-boosted lopinavir (Ritonavir-boosted lopinavir) — Bamrasnaradura Infectious Diseases Institute.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ritonavir-boosted lopinavir TARGET | Ritonavir-boosted lopinavir | Bamrasnaradura Infectious Diseases Institute | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ritonavir-boosted lopinavir CI watch — RSS
- Ritonavir-boosted lopinavir CI watch — Atom
- Ritonavir-boosted lopinavir CI watch — JSON
- Ritonavir-boosted lopinavir alone — RSS
Cite this brief
Drug Landscape (2026). Ritonavir-boosted lopinavir — Competitive Intelligence Brief. https://druglandscape.com/ci/ritonavir-boosted-lopinavir. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab